Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II

被引:156
|
作者
vantVeer, C [1 ]
Mann, KG [1 ]
机构
[1] UNIV VERMONT, DEPT BIOCHEM, BURLINGTON, VT 05405 USA
关键词
D O I
10.1074/jbc.272.7.4367
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The effects of the stoichiometric inhibitors tissue factor pathway inhibitor (TFPI), antithrombin-III (AT-III) and heparin cofactor-II (HC-II) on thrombin generation were evaluated in a reaction system composed of coagulation factors VIIa, X, IX, VIII, and V and prothrombin initiated by tissue factor (TF) and phospholipids. Initiation of the reaction in the absence of inhibitors resulted in explosive thrombin generation for factor VIIa-TF concentrations varying from 100 to 0.25 pM with the lag time or initiation phase of thrombin generation increasing from 0 to 180 s with decreasing factor VIIa-TF concentrations, During the propagation phase, prothrombin is quantitatively activated to 1.4 mu M alpha-thrombin. At normal plasma concentration (2.5 nM) full-length recombinant TFPI prolonged the initiation phase of thrombin generation 2-fold, and the rate of thrombin generation in the propagation phase of the reaction was 25-50% that of the uninhibited reaction when the reaction was initiated with 1.25-20 pM factor VIIa-TF. Inhibition of the reaction by TFPI is associated with a delay in factor V activation, In the presence of TFPI no explosive thrombin generation was observed when factor VIII was omitted from reactions initiated by factor VIIa-TF concentrations less than or equal to 20 pM. This indicates that in the presence of TFPI the factor Ma factor VIIIa pathway becomes essential at low factor VIIa-TF concentrations. In the reconstituted system, AT-III (3.4 mu M) did not prolong the initiation phase of thrombin generation when the reaction was initiated with 1.25 pM factor VIIa-TF, nor did AT-III delay factor V activation. The rate of thrombin formation in the presence of AT-III was reduced to 30% that of the uninhibited reaction, and the cu-thrombin formed was rapidly inhibited subsequent to its generation, The addition of HC-II alone at its physiological concentration (1.38 mu M) to the procoagulant mixture did not alter the rate or extent of thrombin generation. Subsequently, the thrombin formed was slowly inhibited by HC-II. The slow inactivation of thrombin by HC-II does not contribute to thrombin inhibition in the presence of AT-III. In contrast, the combination of physiological levels of AT-III and TFPI inhibited explosive thrombin generation initiated by 1.25 pM factor Wa TF completely, The absence of prothrombin consumption indicated that the combination of TFPI and AT-III is able to prevent the formation of prothrombinase activity at low factor VIIa-TF concentrations, The data indicate that TFPI potentiates the action of AT-III by decreasing the rate of formation and thus the amount of catalyst formed in the reaction, enabling AT-III to effectively scavenge the limited traces of factor IXa and factor Xa formed in the presence of TFPI, The initiation of thrombin generation by increasing factor VIIa-TF concentrations in the presence of physiological concentrations of TFPI and AT-III showed dramatic changes in the maximal rates of thrombin generation over small changes in initiator concentration, These data demonstrate that significant thrombin generation becomes a ''threshold-limited'' event with regard to the initiating factor VIIa-TF concentration in the presence of TFPI and AT-III.
引用
收藏
页码:4367 / 4377
页数:11
相关论文
共 50 条
  • [31] PREVENTION OF THROMBUS FORMATION AND GROWTH BY ANTITHROMBIN-III AND HEPARIN-COFACTOR-II DEPENDENT THROMBIN INHIBITORS - IMPORTANCE OF HEPARIN-COFACTOR-II
    BUCHANAN, MR
    LIAO, P
    SMITH, LJ
    OFOSU, FA
    THROMBOSIS RESEARCH, 1994, 74 (05) : 463 - 475
  • [32] INHIBITION OF THROMBIN BY ANTITHROMBIN-III AND HEPARIN-COFACTOR-II IN-VIVO
    LIU, LB
    DEWAR, L
    SONG, YQ
    KULCZYCKY, M
    BLAJCHMAN, MA
    FENTON, JW
    ANDREW, M
    DELORME, M
    GINSBERG, J
    PREISSNER, KT
    OFOSU, FA
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (03) : 405 - 412
  • [33] A NEW BIOLOGICAL METHOD OF ANTITHROMBIN-III ASSAY WITHOUT INFLUENCE OF HEPARIN COFACTOR-II
    ENOMOTO, M
    TANIMIZU, I
    SAKURAGAWA, N
    THROMBOSIS AND HAEMOSTASIS, 1989, 62 (01) : 384 - 384
  • [34] REACTIVE SITE PEPTIDE STRUCTURAL SIMILARITY BETWEEN HEPARIN COFACTOR-II AND ANTITHROMBIN-III
    GRIFFITH, MJ
    NOYES, CM
    CHURCH, FC
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1985, 260 (04) : 2218 - 2225
  • [35] INCREASED CONCENTRATIONS OF HEPARIN COFACTOR-II IN DIABETIC-PATIENTS, AND POSSIBLE EFFECTS ON THROMBIN INHIBITION ASSAY OF ANTITHROMBIN-III
    GRAM, J
    JESPERSEN, J
    CLINICAL CHEMISTRY, 1989, 35 (01) : 52 - 55
  • [36] COMPARATIVE-STUDIES OF HEPARIN-COFACTOR ACTIVITY TOWARD ANTITHROMBIN-III AND HEPARIN COFACTOR-II, AND ANTITHROMBIN-III AFFINITY BETWEEN LOW-MOLECULAR-WEIGHT HEPARIN AND UNFRACTIONATED HEPARIN
    SHIMOTORI, T
    SAKURAGAWA, N
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1990, 16 : 71 - 76
  • [37] ANTITHROMBIN-III AFFINITY DEPENDENCE ON THE ANTICOAGULANT, ANTIPROTEASE, AND TISSUE FACTOR PATHWAY INHIBITOR ACTIONS OF HEPARINS
    JESKE, W
    LORMEAU, JC
    CALLAS, D
    IQBAL, O
    HOPPENSTEADT, D
    FAREED, J
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1995, 21 (02): : 193 - 200
  • [38] The contribution of Tissue Factor Pathway Inhibitor to Thrombin Generation in children receiving Unfractionated Heparin
    Hiremath, Mandira
    Newall, Fiona
    Ignjatovic, Vera
    Summerhayes, Robyn
    Monagle, Paul
    THROMBOSIS RESEARCH, 2011, 127 (03) : 275 - 276
  • [39] DIFFERENT GLYCOFORMS OF HUMAN THROMBOMODULIN - THEIR GLYCOSAMINOGLYCAN-DEPENDENT MODULATORY EFFECTS ON THROMBIN INACTIVATION BY HEPARIN COFACTOR-II AND ANTITHROMBIN-III
    KOYAMA, T
    PARKINSON, JF
    SIE, P
    BANG, NU
    MULLERBERGHAUS, G
    PREISSNER, KT
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1991, 198 (03): : 563 - 570
  • [40] ANTITHROMBIN-III AND HEPARIN COFACTOR-II IN DIABETIC-PATIENTS - ABNORMAL PROFILES IN CROSSED IMMUNOELECTROPHORESIS
    DUBOSCQ, C
    QUINTANA, I
    BARROS, J
    KORDICH, L
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 1136 - 1136